| Literature DB >> 27863412 |
Abstract
Recent studies explored XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer (OC) risk. However, the association between these two single nucleotide polymorphisms and OC risk remains conflicting. Thus, we conducted a comprehensive systematic review and meta-analysis to investigate the association. We searched the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. 15 case-control studies published in 11 papers including 4,757 cases and 8,431 controls were included in this meta-analysis. No associations were obtained between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk. Stratification analyses of Hardy-Weinberg equilibrium status indicated that rs3218536 polymorphism was associated with the decreased risk of OC when in analysis of combined HWE positive studies. In conclusion, this meta-analysis indicates that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with the risk of OC.Entities:
Keywords: ERCC2; XRCC2; meta-analysis; ovarian cancer; single nucleotide polymorphism
Mesh:
Substances:
Year: 2016 PMID: 27863412 PMCID: PMC5349940 DOI: 10.18632/oncotarget.13361
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Selection for eligible citations included in this meta-analysis
Characteristics of included studies
| Author and year | Country | Genotype method | SOC | Ethnicity | Case | Control | HWE | NOS | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XRCC2 rs3218536 | Arg/Arg | Arg/His | His/His | Arg/Arg | Arg/His | His/His | ||||||
| Auranen_2005a | UK | TaqMan | PB | Caucasian | 629 | 98 | 2 | 704 | 129 | 9 | Y | 6 |
| Auranen_2005b | Denmark | PCR | PB | Caucasian | 260 | 54 | 1 | 331 | 68 | 5 | Y | 6 |
| Auranen_2005c | USA | PCR | PB | Caucasian | 238 | 31 | 0 | 484 | 75 | 2 | Y | 7 |
| Auranen_2005d | UK | PCR | PB | Caucasian | 251 | 23 | 1 | 1538 | 267 | 6 | Y | 6 |
| Webb_2005a | Australia | PCR-RFLP | HB | Caucasian | 364 | 63 | 3 | 802 | 140 | 8 | Y | 5 |
| Webb_2005b | Australia | PCR-RFLP | HB | Mixed | 87 | 5 | 2 | 150 | 16 | 2 | Y | 7 |
| Beesley_2007 | Australia | MALDI-TOF | PB | Caucasian | 799 | 117 | 7 | 696 | 115 | 7 | Y | 6 |
| Mohamed_2013 | Egypt | PCR | HB | Caucasian | 6 | 58 | 36 | 16 | 60 | 24 | N | 6 |
| Michalska_2016 | Poland | PCR-RFLP | PB | Caucasian | 120 | 80 | 500 | 180 | 400 | 120 | N | 7 |
| Lys/Lys | Lys/Gln | Gln/Gln | Lys/Lys | Lys/Gln | Gln/Gln | |||||||
| Costa_2007 | Portugal | PCR-RFLP | HB | Caucasian | 55 | 49 | 22 | 95 | 95 | 12 | Y | 7 |
| Bernard-Gallon_2008 | France | TaqMan | HB | Caucasian | 1 | 31 | 19 | 119 | 446 | 430 | Y | 5 |
| Jakubowska_2010 | Poland | PCR | HB | Caucasian | 58 | 65 | 22 | 100 | 123 | 57 | Y | 6 |
| Mohamed_2013 | Egypt | PCR | HB | Caucasian | 32 | 54 | 14 | 55 | 35 | 10 | Y | 7 |
| Monteiro_2014 | Brazil | PCR-RFLP | HB | Caucasian | 33 | 36 | 1 | 37 | 30 | 3 | Y | 6 |
| Michalska_2015 | Poland | PCR-RFLP | PB | Caucasian | 62 | 64 | 304 | 96 | 240 | 94 | Y | 6 |
SOC, source of controls; PB, population-based controls; HB, hospital-based controls; HWE, Hardy–Weinberg equilibrium; NOS, Newcastle-Ottawa Scale
Meta-analysis of association between ERCC2 rs13181, XRCC2 rs3218536 polymorphisms and OC risk
| Genetic models | OR(95%CI) | I2 (%) | Model | ||
|---|---|---|---|---|---|
| Allele | 1.45(0.83,2.54) | 0.188 | < 0.001 | 93.8 | Random |
| Dominant | 1.45(0.99,2.14) | 0.058 | 0.010 | 66.7 | Random |
| Recessive | 1.56(0.49,4.93) | 0.447 | < 0.001 | 95.0 | Random |
| Allele | 1.05(0.61,1.82) | 0.852 | < 0.001 | 96.4 | Random |
| Dominant | 0.96(0.74,1.24) | 0.759 | < 0.001 | 75.0 | Random |
| Recessive | 1.11(0.34,3.63) | 0.862 | < 0.001 | 91.7 | Random |
Figure 2Forest plot shows odds ratio for the associations between ERCC2 rs13181 polymorphism and OC risk (Dominant model)
Summary of the subgroup analyses in this meta-analysis
| Comparison | Category | Category | Studies | OR (95% CI) | |
|---|---|---|---|---|---|
| Allele | SOC | PB | 6 | 1.04(0.49,2.19) | 0.926 |
| HB | 3 | 1.13(0.77,1.66) | 0.535 | ||
| HWE | Positive | 7 | 0.84(0.74,0.95) | 0.006 | |
| Negative | 2 | 2.57(1.03,6.38) | 0.042 | ||
| Ethnicity | Caucasian | 8 | 1.08(0.61,1.94) | 0.783 | |
| Asian | 1 | 0.79(0.35,1.78) | 0.577 | ||
| Dominant | SOC | PB | 6 | 0.91(0.67,1.24) | 0.556 |
| HB | 3 | 1.17(0.59,2.33) | 0.649 | ||
| HWE | Positive | 7 | 0.83(0.73,0.95) | 0.007 | |
| Negative | 2 | 1.74(1.36,2.24) | <0.001 | ||
| Ethnicity | Caucasian | 8 | 0.98(0.75,1.28) | 0.887 | |
| Asian | 1 | 0.67(0.27,1.67) | 0.390 | ||
| Recessive | SOC | PB | 6 | 0.92(0.15,5.80) | 0.932 |
| HB | 3 | 1.57(0.92,2.69) | 0.098 | ||
| HWE | Positive | 7 | 0.69(0.37,1.26) | 0.225 | |
| Negative | 2 | 4.74(0.73,30.96) | 0.104 | ||
| Ethnicity | Caucasian | 8 | 1.05(0.29,3.73) | 0.943 | |
| Asian | 1 | 1.80(0.25,13.02) | 0.558 | ||
| Allele | SOC | HB | 5 | 1.19(0.89,1.59) | 0.248 |
| PB | 1 | 3.61(2.93,4.45) | <0.001 | ||
| Dominant | SOC | HB | 5 | 1.41(0.86,2.32) | 0.168 |
| PB | 1 | 1.71(1.20,2.43) | 0.003 | ||
| Recessive | SOC | HB | 5 | 1.13(0.58,2.19) | 0.726 |
| PB | 1 | 8.62(6.33,11.75) | <0.001 | ||
Figure 3Stratification analyses by source of control between ERCC2 rs13181 polymorphism and OC risk (Dominant model)
Figure 4Sensitivity analysis about XRCC2 rs3218536 polymorphism and OC risk (Recessive model)
Figure 5Sensitivity analysis about ERCC2 rs13181 polymorphism and OC risk (Dominant model)